W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

12 September, 2024

Position of the Transparency Council – Livtencity (maribavir)

12 September, 2024

Position of the Transparency Council – Calquence (acalabrutinib)

11 September, 2024

Recommendation of the President – Veoza (fezolinetant)

11 September, 2024

The Transparency Council meeting 39/2024 on 16 September 2024

11 September, 2024

Recommendation of the President – Ferriprox (deferiprone)

11 September, 2024

Opinion of the President – prevention and early detection of prostate cancer among the residents of the municipality of Polkowice

11 September, 2024

Opinion of the President – prevention of early detection of eye defects and strabismus in children aged 5-6 years

06 September, 2024

Communication of the meeting of Transparency Council No. 37/2024/2024 on 2 September 2024

06 September, 2024

Opinion of the Transparency Council – ciclosporinum

06 September, 2024

Opinion of the Transparency Council – theophyllinum

06 September, 2024

Opinion of the Transparency Council – azathioprinum

06 September, 2024

Opinion of the Transparency Council – phenoxymethylpenicillinum

06 September, 2024

Position of the Transparency Council – Milupa Basic-f

06 September, 2024

Position of the Transparency Council – Veoza (fezolinetant)

06 September, 2024

Position of the Transparency Council – Ferriprox (deferiprone)

30 August, 2024

Opinion of the Transparency Council – enoxaparinum natricum and nadroparinum calcicum

30 August, 2024

Opinion of the Transparency Council – expansion of the chemotherapy catalog in appendix C.22

30 August, 2024

Opinion of the Transparency Council – trabektedine

30 August, 2024

Opinion of the Transparency Council – axitinib

30 August, 2024

Opinion of the Transparency Council – temsilrolimus

30 August, 2024

Opinion of the Transparency Council – panitumumab

30 August, 2024

Opinion of the Transparency Council – cetuximab B.4

30 August, 2024

Opinion of the Transparency Council – cetuximab B.52

30 August, 2024

Position of the Transparency Council – Kinpeygo (budesonide)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑